These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 16164268)
1. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment]. Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268 [TBL] [Abstract][Full Text] [Related]
2. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
3. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group]. Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414 [TBL] [Abstract][Full Text] [Related]
4. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115 [TBL] [Abstract][Full Text] [Related]
5. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. Kim JC; Steinberg GD J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460 [TBL] [Abstract][Full Text] [Related]
6. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts. Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729 [TBL] [Abstract][Full Text] [Related]
8. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome. Zieger K; Jensen KM Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636 [TBL] [Abstract][Full Text] [Related]
9. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798 [TBL] [Abstract][Full Text] [Related]
10. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate. Palou J; Xavier B; Laguna P; Montlleó M; Vicente J Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder]. Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817 [TBL] [Abstract][Full Text] [Related]
14. Stromal invasion of the prostate following a complete response to bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the ureter and the bladder. Hara I; Yao A; Muramaki M; Hikosaka S; Yamada Y; Kawabata G; Kamidono S Int J Urol; 2004 Apr; 11(4):250-2. PubMed ID: 15028107 [TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra. Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432 [TBL] [Abstract][Full Text] [Related]
16. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?]. Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270 [TBL] [Abstract][Full Text] [Related]
17. [T1 G3 bladder tumors: the respective role of BCG and cystectomy]. Pfister C; Landé P; Hervé JM; Barré P; Barbagelatta M; Camey M; Botto H Prog Urol; 1995 Apr; 5(2):231-7. PubMed ID: 7719369 [TBL] [Abstract][Full Text] [Related]
18. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523 [TBL] [Abstract][Full Text] [Related]
19. [Carcinoma in situ of the bladder involving the prostate with an unusual invasive pattern following BCG therapy: a case report]. Iba A; Kohjimoto Y; Inagaki T; Suzuki A; Fujii R; Senzaki H; Uekado Y; Shinka T Hinyokika Kiyo; 2005 Oct; 51(10):681-4. PubMed ID: 16285623 [TBL] [Abstract][Full Text] [Related]
20. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]